Affordable Access

deepdyve-link
Publisher Website

Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment

Authors
  • Shariq, Omair A.
  • McKenzie, Travis J.
Type
Published Article
Journal
Therapeutic Advances in Chronic Disease
Publisher
SAGE Publications
Publication Date
Jul 20, 2021
Volume
12
Identifiers
DOI: 10.1177/20406223211033103
PMID: 34349894
PMCID: PMC8295938
Source
PubMed Central
Keywords
Disciplines
  • New Perspectives in the Diagnosis and Treatment of Endocrine Cancer
  • Review
License
Unknown

Abstract

Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with an annual incidence of ~1 case per million population. Differentiating between ACC and benign adrenocortical tumors can be challenging in patients who present with an incidentally discovered adrenal mass, due to the limited specificity of standard diagnostic imaging. Recently, urine steroid metabolite profiling has been prospectively validated as a novel diagnostic tool for the detection of malignancy with improved accuracy over current modalities. Surgery represents the only curative treatment for ACC, although local recurrence and metastases are common, even after a margin-negative resection is performed. Unlike other intra-abdominal cancers, the role of minimally invasive surgery and lymphadenectomy in ACC is controversial. Adjuvant therapy with the adrenolytic drug mitotane is used to reduce the risk of recurrence after surgery, although evidence supporting its efficacy is limited; it is also currently unclear whether all patients or a subset with the highest risk of recurrence should receive this treatment. Large-scale pan-genomic studies have yielded insights into the pathogenesis of ACC and have defined distinct molecular signatures associated with clinical outcomes that may be used to improve prognostication. For patients with advanced ACC, palliative combination chemotherapy with mitotane is the current standard of care; however, this is associated with poor response rates (RR). Knowledge from molecular profiling studies has been used to guide the development of novel targeted therapies; however, these have shown limited efficacy in early phase trials. As a result, there is an urgent unmet need for more effective therapies for patients with this devastating disease.

Report this publication

Statistics

Seen <100 times